The Trump Administration has repeatedly promised to bring “gold standard science” back to federal health policy. President Trump’s August 10 executive order (EO) is the latest action in this revisionist arc, establishing new “Gold Standard Childhood Vaccine Recommendations.” The order reduces the diseases for which immunization is universally recommended, and pushes hepatitis A and B, rotavirus, influenza, and other vaccines, toward narrower recommendations or shared clinical decision-making, in line with prior attempts currently being litigated in court. It encourages states to reconsider school vaccination requirements, calls for separating the combined measles-mumps-rubella (MMR) vaccine into individual shots, and says childhood immunizations should be administered at separate medical visits. Rather than updating federal policy in alignment with public health data, the EO puts politics and medical skepticism in the driver’s seat.

The administration’s recurring justification is that the United States recommends more childhood vaccines than peer countries: Count how many vaccines other countries recommend, note that the United States recommends more, and treat the difference as evidence that the American schedule must be excessive. Its January assessment repeatedly emphasizes that the United States vaccinates against more diseases and administers more doses than countries such as Denmark (a favorite administration reference). Yet that is not a convincing scientific standard, and it is an especially weak foundation for remaking a vaccination system with a long record of preventing disease and reducing costs.

Different countries have different disease burdens, health systems, patterns of transmission, access to care, and vaccination strategies. International comparison can help identify useful questions, but it cannot answer them merely by showing that one schedule is slimmer than another. The administration’s fixation on the number of recommended doses reduces a complicated public health assessment to numerology. The U.S. vaccine schedule has expanded since 1980 because vaccines became available to prevent additional diseases; an increase in the number of effective preventive tools is not, by itself, evidence of overtreatment.

Consider varicella. Before routine vaccination, the United States experienced roughly 4 million cases of chickenpox annually. As discussed last year in American Action Forum work, vaccination prevented an estimated 91 million cases, 238,000 hospitalizations, and nearly 2,000 deaths over 25 years, while generating an estimated $23.4 billion in net societal savings. That some European countries have taken a different approach does not diminish those benefits.

The economic record is compelling across the broader pediatric schedule. Routine childhood immunizations among children born from 1994 through 2023 are estimated to have prevented approximately 508 million illnesses, 32 million hospitalizations, and 1.13 million deaths, producing about $540 billion in direct medical savings and $2.7 trillion in societal savings. Every dollar spent on childhood immunization returned roughly $11. If the administration seeks to overturn that extraordinarily successful status quo, the appropriate burden should be to demonstrate that specific recommendations no longer produce sufficient benefit, not simply to point to a shorter list in Copenhagen.

The administration’s MMR proposal makes the EO’s internal inconsistency especially difficult to defend. The administration wants measles, mumps, and rubella vaccines administered separately once individual products become available and generally wants childhood vaccines spread across separate visits. Yet the Department of Health and Human Services’ own assessment praises Denmark for reducing injections through a pentavalent vaccine protecting against five diseases at once. Denmark’s schedule works in part because it combines vaccines efficiently, while the administration has somehow converted that observation into a U.S. policy of pulling them apart. Rather than following Denmark’s model, the policy selectively borrows the elements that support a predetermined conclusion.

Additional visits are also not costless. They mean more appointments, transportation costs, and time away from work for parents and school for children. These are all barriers that could impede getting future vaccine doses – which is likely the point – while vaccination rates are already deteriorating. MMR coverage among kindergartners has fallen below the roughly 95-percent target for herd immunity to 92.5 percent in the 2024–2025 school year. Policymakers should be wary of adding friction that could cause coverage to plunge further, particularly as ongoing measles outbreaks demonstrate the consequences of allowing sufficiently large pockets of susceptibility to develop.

There may be aspects of the administration’s agenda worth preserving. Vaccine safety surveillance can always improve and better evidence is welcome. But rebuilding trust – as the administration claims – does not require treating every suspicion as equally supported by evidence, nor does an appeal to parental choice eliminate the externalities inherent in infectious disease.

Gold standard science should mean evaluating evidence consistently and following it wherever it leads. The administration instead began with its desired conclusion – that the U.S. vaccinates children too much – and constructed a policy framework around it. But if the administration wants to remake a system that has prevented hundreds of millions of illnesses and generated enormous economic returns, it should be prepared to show that its alternative will produce better outcomes. So far, the administration has not demonstrated that preventing less disease will make American children healthier.